//
sign in
Post
by @danabra.mov
PostEmbed
by @danabra.mov
Record
by @jimpick.com
Record
by @atsui.org
+ new component
Post
The @US_FDA approved the targeted therapy capivasertib with the hormone therapy abiraterone and the steroid prednisone for adults with PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer: buff.ly/DD3a27z
19h
On June 12, 2026, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca) in combination with abiraterone and prednisone for adults with metastatic androgen pathway…
www.fda.gov
FDA approves capivasertib with abiraterone and prednisone for PTEN-def
American Association for Cancer Research (AACR)